April 2018 in “Journal of Investigative Dermatology” This study suggests that for dermatomyositis patients with minimal skin disease activity, further improvement in cutaneous symptoms may not translate into better quality of life, highlighting a need to revise trial endpoints.
19 citations
,
September 2010 in “Journal of the European Academy of Dermatology and Venereology” This study found that while the CLASI is generally useful for assessing disease activity and damage in cutaneous lupus erythematosus, it may not accurately reflect all subtypes, indicating a need for revision.
March 2026 in “SKIN The Journal of Cutaneous Medicine” This study demonstrated that litifilimab significantly reduced disease activity in cutaneous lupus erythematosus by Week 16, with improvements most notable in sunlight-exposed skin areas.
7 citations
,
March 2023 in “Antioxidants” This study confirmed the antioxidant role of rosemary, suggesting its potential use in treating inflammatory and infectious skin conditions, but emphasizes that more large-scale controlled trials are necessary to fully understand its clinical impact.
January 2025 in “Journal of Investigative Dermatology”